Table 3.
Association of ABCD-GENE Score with Ischemic Outcomes within 1-Year After Percutaneous Coronary Intervention
| No. of events | Event rate per 100 person-years | Unadjusted HR | Adjusted HRa | |
|---|---|---|---|---|
| Major atherothrombotic events | ||||
| ABCD-GENE score <10 (n=1836) |
150 | 14.7 (95% CI, 12.3 – 17.0) |
Reference | Reference |
| ABCD-GENE score ≥10 (n=505) |
62 | 24.6 (95% CI, 18.5 – 30.8) |
1.63 (95% CI, 1.21 – 2.19) p=0.001 |
1.66 (95% CI, 1.23 – 2.25) p<0.001 |
| MACE | ||||
| ABCD-GENE score <10 (n=1836) |
103 | 10.1 (95% CI, 8.1 – 12.0) |
Reference | Reference |
| ABCD-GENE score ≥10 (n=505) |
42 | 16.7 (95% CI, 11.6 – 21.7) |
1.60 (95% CI, 1.12 – 2.29) p=0.011 |
1.59 (95% CI, 1.11 – 2.30) p=0.013 |
a
Model adjusted for: sex, smoking status, percutaneous coronary intervention (PCI) indication (i.e., MI vs. UA or elective PCI), PCI strategy (i.e., stent versus percutaneous transluminal coronary angioplasty), and institution
ABCD-GENE (Age, oBesity, Chronic kidney disease, Diabetes, CYP2C19 GENEtic variants) score; MACE, major adverse cardiovascular events. Major atherothrombotic events defined as the composite of death, myocardial infarction (MI), ischemic stroke, stent thrombosis (ST), or unstable (UA) requiring revascularization. MACE defined as the composite of cardiovascular death, MI, ST, or ischemic stroke.